Luoxis Diagnostics, Inc. recently presented three clinical and preclinical findings that feature the company’s proprietary RedoxSYS™ Diagnostic System as a comprehensive, groundbreaking tool for research capable of assessing a patient’s oxidation-reduction potential (ORP) in the event of injury, illness, or stress. The findings were presented as peer-reviewed posters during the recently concluded 21st annual meeting of The Society for Free Radical Biology and Medicine (SFBRM), last weekend, November 19-23 in Seattle, Washington.
The international conference was attended by over 500 researchers with a specialization on oxidative stress. Two of Luoxis’ studies used the RedoxSYS system and mice models to examine the ability of experimental antioxidant therapies to lessen oxidative stress in neurodegenerative diseases Parkinson’s and multiple sclerosis. The 3rd study demonstrated the system’s ability to quickly and non-invasively evaluate exercise-induced oxidative stress in athletes.
In the study that used RedoxSYS to study oxidative stress in mice with Parkinson’s disease, static ORP (sORP) was found to be a reliable biomarker of oxidative stress, which can be used to determine the severity of the disease and the patient’s response to treatment. In the study that focused on multiple sclerosis, changes in mice’s brain tissue ORP were examined, which exhibited RedoxSYS’ groundbreaking sensitivity to even the slightest fluctuations in ORP.
“These research studies serve as important foundational evidence for the versatile applicability and broad potential of our novel RedoxSYS platform,” said Josh Disbrow, Luoxis’ President and Chief Executive Officer. “We are grateful to our partners for helping us to validate our first-in-class product, which may not only have potential as an acute care clinical diagnostic system, but also as a valuable research tool that could facilitate and possibly accelerate the development of future therapies for a wide range of diseases. We are continuing to pursue global research collaborations as part of our ongoing market development strategy, and we look forward to sharing additional updates on our progress.”
The RedoxSYS Diagnostic System from Luoxis, an Ampio Pharmaceuticals subsidiary, is the first and only clinical diagnostic technology that has the ability to accurately measure redox potential or oxidation-reduction potential from as little as 20 to 40 microliters of a biological sample such as plasma, serum, CSF, or urine. Results are generated in as little as 4 minutes.